Indications and uses
• treats migraine
• treats migraine
• do not use more than directed • adults: take 2 caplets with a glass of water • if symptoms persist or worsen, ask your doctor • do not take more than 2 caplets in 24 hours, unless directed by a doctor • under 18 years of age: ask a doctor
• store at controlled room temperature 20°-25°C (68°-77°F) • close cap tightly after use • read all product information before using. Keep this box for important information.
Acetaminophen 250 mg
Aspirin 250 mg (NSAID*)
Caffeine 65 mg
* nonsteroidal anti-inflammatory drug
Pain reliever
Pain reliever
Pain reliever aid
Reye’s syndrome: Children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. When using this product, if changes in behavior with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of Reye’s syndrome, a rare but serious illness.
Allergy alert: Acetaminophen may cause severe skin reactions. Symptoms may include:
If a skin reaction occurs, stop use and seek medical help right away.
Allergy alert: Aspirin may cause a severe allergic reaction which may include:
Liver warning: This product contains acetaminophen. Severe liver damage may occur if you take
Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you
Medication overuse headache warning: Headaches may worsen if this product is used for 10 or more days per month.
Caffeine warning: The recommended dose of this product contains about as much caffeine as a cup of coffee. Limit the use of caffeine-containing medications, foods, or beverages while taking this product because too much caffeine may cause nervousness, irritability, sleeplessness, and, occasionally, rapid heart beat.
ask a health professional before use. It is especially important not to use aspirin during the last 3 months of pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
In case of overdose, get medical help or contact a Poison Control Center right away. Quick medical attention is critical for adults as well as for children even if you do not notice any signs or symptoms.
benzoic acid, carnauba wax, FD&C blue #1, hydroxypropylcellulose, hypromellose, light mineral oil, microcrystalline cellulose, polysorbate 20, povidone, propylene glycol, simethicone emulsion, sorbitan monolaurate, stearic acid, titanium dioxide
1-800-468-7746
NDC 0067-2039-24
See new warnings information
EXCEDRIN®
MIGRAINE
Acetaminophen, Aspirin (NSAID) and Caffeine
Pain Reliever/Pain Reliever Aid
24
CAPLETS*
*CAPSULE-SHAPED TABLETS
TAMPER-EVIDENT BOTTLE
DO NOT USE IF INNER FOIL SEAL IMPRINTED WITH “SEALED for YOUR PROTECTION” IS BROKEN OR MISSING
Distributed by: GSK Consumer Healthcare, Warren, NJ 07059
©2017 GSK or its licensor.
Visit us at
www.excedrin.com
62000000012933

| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 308297 | acetaminophen 250 MG / aspirin 250 MG / caffeine 65 MG Oral Tablet | PSN | 14 |
| 209468 | EXCEDRIN 250 MG / 250 MG / 65 MG Oral Tablet | PSN | 14 |
| 209468 | acetaminophen 250 MG / aspirin 250 MG / caffeine 65 MG Oral Tablet [Excedrin] | SBD | 14 |
| 308297 | acetaminophen 250 MG / aspirin 250 MG / caffeine 65 MG Oral Tablet | SCD | 14 |
| 308297 | APAP 250 MG / ASA 250 MG / caffeine 65 MG Oral Tablet | SY | 14 |
| 209468 | APAP 250 MG / ASA 250 MG / Caffeine 65 MG Oral Tablet [Excedrin] | SY | 14 |
| 209468 | Excedrin Extra Strength (APAP 250 MG / ASA 250 MG / caffeine 65 MG) Oral Tablet | SY | 14 |
| 209468 | Excedrin Menstrual Complete (APAP 250 MG / ASA 250 MG / caffeine 65 MG) Oral Tablet | SY | 14 |
| 209468 | Excedrin Migraine (APAP 250 MG / ASA 250 MG / caffeine 65 MG) Oral Tablet | SY | 14 |
| Class | Version | Type | Effective |
|---|---|---|---|
| ASPIRIN Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20191108 |
| CAFFEINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0067-2039-02 | EXCEDRINMIGRAINE | 2 in 1 POUCH | TABLET, FILM COATED | 2 | 14 | |
| 0067-2039-07 | EXCEDRINMIGRAINE | 250 in 1 BOTTLE | TABLET, FILM COATED | 250 | 14 | |
| 0067-2039-08 | EXCEDRINMIGRAINE | 1 in 1 CARTON | TABLET, FILM COATED | 1 | 14 | |
| 0067-2039-08 | EXCEDRINMIGRAINE | 8 in 1 BOTTLE | TABLET, FILM COATED | 8 | 14 | |
| 0067-2039-09 | EXCEDRINMIGRAINE | 1 in 1 CARTON | TABLET, FILM COATED | 1 | 14 | |
| 0067-2039-09 | EXCEDRINMIGRAINE | 10 in 1 BOTTLE | TABLET, FILM COATED | 10 | 14 | |
| 0067-2039-24 | EXCEDRINMIGRAINE | 1 in 1 CARTON | TABLET, FILM COATED | 1 | 14 | |
| 0067-2039-24 | EXCEDRINMIGRAINE | 24 in 1 BOTTLE | TABLET, FILM COATED | 24 | 14 | |
| 0067-2039-30 | EXCEDRINMIGRAINE | 1 in 1 CARTON | TABLET, FILM COATED | 1 | 14 | |
| 0067-2039-30 | EXCEDRINMIGRAINE | 30 in 1 BOTTLE | TABLET, FILM COATED | 30 | 14 | |
| 0067-2039-33 | EXCEDRINMIGRAINE | 300 in 1 BOTTLE | TABLET, FILM COATED | 300 | 14 | |
| 0067-2039-33 | EXCEDRINMIGRAINE | 1 in 1 CARTON | TABLET, FILM COATED | 1 | 14 | |
| 0067-2039-50 | EXCEDRINMIGRAINE | 50 in 1 BOTTLE | TABLET, FILM COATED | 50 | 14 | |
| 0067-2039-50 | EXCEDRINMIGRAINE | 1 in 1 CARTON | TABLET, FILM COATED | 1 | 14 | |
| 0067-2039-77 | EXCEDRINMIGRAINE | 250 in 1 BOTTLE | TABLET, FILM COATED | 250 | 14 | |
| 0067-2039-77 | EXCEDRINMIGRAINE | 1 in 1 CARTON | TABLET, FILM COATED | 1 | 14 | |
| 0067-2039-83 | EXCEDRINMIGRAINE | 1 in 1 CARTON | TABLET, FILM COATED | 1 | 14 | |
| 0067-2039-83 | EXCEDRINMIGRAINE | 125 in 1 BOTTLE | TABLET, FILM COATED | 125 | 14 | |
| 0067-2039-84 | EXCEDRINMIGRAINE | 125 in 1 BOTTLE | TABLET, FILM COATED | 125 | 14 | |
| 0067-2039-86 | EXCEDRINMIGRAINE | 125 in 1 BOTTLE | TABLET, FILM COATED | 125 | 14 | |
| 0067-2039-86 | EXCEDRINMIGRAINE | 1 in 1 CARTON | TABLET, FILM COATED | 1 | 14 | |
| 0067-2039-91 | EXCEDRINMIGRAINE | 1 in 1 CARTON | TABLET, FILM COATED | 1 | 14 | |
| 0067-2039-91 | EXCEDRINMIGRAINE | 100 in 1 BOTTLE | TABLET, FILM COATED | 100 | 14 | |
| 0067-2039-92 | EXCEDRINMIGRAINE | 1 in 1 CARTON | TABLET, FILM COATED | 1 | 14 | |
| 0067-2039-92 | EXCEDRINMIGRAINE | 200 in 1 BOTTLE | TABLET, FILM COATED | 200 | 14 | |
| 0067-2039-94 | EXCEDRINMIGRAINE | 100 in 1 BOTTLE | TABLET, FILM COATED | 100 | 14 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0067-2039-08 | EA - Each | 0067-2039 | 16ce8a4b-bd70-4a64-ad07-8ff387eb6638 | 1 | 2012-07-24 |
| 0067-2039-24 | EA - Each | 0067-2039 | bbb39c99-180a-437a-85d0-e53a1eb91ead | 1 | 2012-07-24 |
| 0067-2039-33 | EA - Each | 0067-2039 | 7b55aa5b-c0f7-4ea7-b9a8-55228dc5e474 | 1 | 2014-09-03 |
| 0067-2039-50 | EA - Each | 0067-2039 | 22e8dd78-54d4-44ec-a754-b64ce6da0b27 | 1 | 2012-07-24 |
| 0067-2039-77 | EA - Each | 0067-2039 | e7beb6f2-112b-44d1-bc0c-8cc047750441 | 1 | 2012-07-24 |
| 0067-2039-83 | EA - Each | 0067-2039 | aeb6329a-c0f6-4dbe-89e3-ff583f2b8adc | 1 | 2024-04-05 |
| 0067-2039-86 | EA - Each | 0067-2039 | dfab005f-c6a2-4e68-af6a-5340d2fe2e83 | 1 | 2015-10-02 |
| 0067-2039-91 | EA - Each | 0067-2039 | baa7e6be-1a22-4946-bd6d-398153fc0397 | 1 | 2012-07-24 |
| 0067-2039-92 | EA - Each | 0067-2039 | 517a3c30-8e99-41dd-8798-e5871b87f0ac | 1 | 2015-02-02 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ACETAMINOPHEN | ACTIVE INGREDIENT | 362O9ITL9D | 6 | |
| ASPIRIN | ACTIVE INGREDIENT | R16CO5Y76E | 6 | |
| CAFFEINE | ACTIVE INGREDIENT | 3G6A5W338E | 6 | |
| ACETAMINOPHEN | ACTIVE MOIETY | 362O9ITL9D | 6 | |
| ASPIRIN | ACTIVE MOIETY | R16CO5Y76E | 6 | |
| CAFFEINE | ACTIVE MOIETY | 3G6A5W338E | 6 | |
| BENZOIC ACID | INACTIVE INGREDIENT | 8SKN0B0MIM | 6 | |
| CARNAUBA WAX | INACTIVE INGREDIENT | R12CBM0EIZ | 6 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 6 | |
| FD&C BLUE NO. 1 | INACTIVE INGREDIENT | H3R47K3TBD | 6 | |
| HYDROXYPROPYL CELLULOSE (TYPE H) | INACTIVE INGREDIENT | RFW2ET671P | 6 | |
| HYPROMELLOSES | INACTIVE INGREDIENT | 3NXW29V3WO | 6 | |
| LIGHT MINERAL OIL | INACTIVE INGREDIENT | N6K5787QVP | 6 | |
| POLYSORBATE 20 | INACTIVE INGREDIENT | 7T1F30V5YH | 6 | |
| POVIDONES | INACTIVE INGREDIENT | FZ989GH94E | 6 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 6 | |
| SORBITAN MONOLAURATE | INACTIVE INGREDIENT | 6W9PS8B71J | 6 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | 6 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 6 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0067-2039 | 0067-2039-02, 0067-2039-08, 0067-2039-09, 0067-2039-24, 0067-2039-30, 0067-2039-50, 0067-2039-94, 0067-2039-91, 0067-2039-83, 0067-2039-84, 0067-2039-86, 0067-2039-92, 0067-2039-77, 0067-2039-07, 0067-2039-33 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LIGHT MINERAL OIL | LIGHT MINERAL OIL | N6K5787QVP | TABLET, FILM COATED / ORAL | 2.49 mg | ||
| HYDROXYPROPYL CELLULOSE (TYPE H) | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET, FILM COATED / ORAL | 131.67 mg | ||
| LIGHT MINERAL OIL | LIGHT MINERAL OIL | N6K5787QVP | TABLET, FILM COATED / ORAL | 2.49 mg | ||
| CARNAUBA WAX | CARNAUBA WAX | R12CBM0EIZ | TABLET, FILM COATED / ORAL | 1 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| LIGHT MINERAL OIL | LIGHT MINERAL OIL | N6K5787QVP | TABLET, FILM COATED / ORAL | 2.49 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED / ORAL | 96 mg | ||
| HYDROXYPROPYL CELLULOSE (TYPE H) | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET, FILM COATED / ORAL | 131.67 mg | ||
| LIGHT MINERAL OIL | LIGHT MINERAL OIL | N6K5787QVP | TABLET, FILM COATED / ORAL | 2.49 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, FILM COATED / ORAL | 176 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, FILM COATED / ORAL | 176 mg | ||
| CARNAUBA WAX | CARNAUBA WAX | R12CBM0EIZ | TABLET, FILM COATED / ORAL | 1 mg | ||
| HYDROXYPROPYL CELLULOSE (TYPE H) | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET, FILM COATED / ORAL | 131.67 mg | ||
| SORBITAN MONOLAURATE | SORBITAN MONOLAURATE | 6W9PS8B71J | TABLET, FILM COATED / ORAL | 800 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED / ORAL | 36 mg | ||
| CARNAUBA WAX | CARNAUBA WAX | R12CBM0EIZ | TABLET, FILM COATED / ORAL | 1 mg | ||
| BENZOIC ACID | BENZOIC ACID | 8SKN0B0MIM | TABLET, FILM COATED / ORAL | NA | ||
| CARNAUBA WAX | CARNAUBA WAX | R12CBM0EIZ | TABLET, FILM COATED / ORAL | 1 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| HYDROXYPROPYL CELLULOSE (TYPE H) | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET, FILM COATED / ORAL | 131.67 mg | ||
| BENZOIC ACID | BENZOIC ACID | 8SKN0B0MIM | TABLET, FILM COATED / ORAL | NA | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| HYDROXYPROPYL CELLULOSE (TYPE H) | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET, FILM COATED / ORAL | 131.67 mg | ||
| BENZOIC ACID | BENZOIC ACID | 8SKN0B0MIM | TABLET, FILM COATED / ORAL | NA | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| HYDROXYPROPYL CELLULOSE (TYPE H) | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET, FILM COATED / ORAL | 131.67 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| LIGHT MINERAL OIL | LIGHT MINERAL OIL | N6K5787QVP | TABLET, FILM COATED / ORAL | 2.49 mg | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | TABLET, FILM COATED / ORAL | 0.35 mg | ||
| HYDROXYPROPYL CELLULOSE (TYPE H) | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET, FILM COATED / ORAL | 131.67 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET, FILM COATED / ORAL | 0.16 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | TABLET, FILM COATED / ORAL | 0.35 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED / ORAL | 582 mg | ||
| HYDROXYPROPYL CELLULOSE (TYPE H) | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET, FILM COATED / ORAL | 131.67 mg | ||
| BENZOIC ACID | BENZOIC ACID | 8SKN0B0MIM | TABLET, FILM COATED / ORAL | NA | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED / ORAL | 582 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED / ORAL | 582 mg | ||
| CARNAUBA WAX | CARNAUBA WAX | R12CBM0EIZ | TABLET, FILM COATED / ORAL | 1 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED / ORAL | 96 mg | ||
| CARNAUBA WAX | CARNAUBA WAX | R12CBM0EIZ | TABLET, FILM COATED / ORAL | 1 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED / ORAL | 582 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET, FILM COATED / ORAL | 0.16 mg | ||
| CARNAUBA WAX | CARNAUBA WAX | R12CBM0EIZ | TABLET, FILM COATED / ORAL | 1 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| SORBITAN MONOLAURATE | SORBITAN MONOLAURATE | 6W9PS8B71J | TABLET, FILM COATED / ORAL | 800 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, FILM COATED / ORAL | 176 mg | ||
| BENZOIC ACID | BENZOIC ACID | 8SKN0B0MIM | TABLET, FILM COATED / ORAL | NA | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, FILM COATED / ORAL | 176 mg | ||
| LIGHT MINERAL OIL | LIGHT MINERAL OIL | N6K5787QVP | TABLET, FILM COATED / ORAL | 2.49 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED / ORAL | 96 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, FILM COATED / ORAL | 176 mg | ||
| CARNAUBA WAX | CARNAUBA WAX | R12CBM0EIZ | TABLET, FILM COATED / ORAL | 1 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, FILM COATED / ORAL | 176 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | TABLET, FILM COATED / ORAL | 0.35 mg | ||
| BENZOIC ACID | BENZOIC ACID | 8SKN0B0MIM | TABLET, FILM COATED / ORAL | NA | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| CARNAUBA WAX | CARNAUBA WAX | R12CBM0EIZ | TABLET, FILM COATED / ORAL | 1 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | ACETAMINOPHEN; ASPIRIN; CAFFEINE | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| EXCEDRIN MIGRAINE | ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE | Haleon US Holdings LLC | 7ed841fb-a61c-4868-b4e5-4f2311a5e79c | 2025-06-25 | Warnings | 0067-2039-84 0067-2039-30 0067-2039-08 0067-2039-07 0067-2039-50 0067-2039-86 0067-2039-02 0067-2039-77 0067-2039-94 0067-2039-92 0067-2039-91 0067-2039-33 0067-2039-09 0067-2039-83 0067-2039-24 0067-2039 00067203907 00067203984 00067203992 00067203924 00067203994 00067203909 00067203977 00067203902 00067203908 00067203950 00067203930 00067203933 00067203983 00067203991 00067203986 7386648a-3c0a-4586-9b61-fd824edfdfc1 7ed841fb-a61c-4868-b4e5-4f2311a5e79c |
Adverse event summaries are temporarily unavailable. Other product information remains available.